Halozyme Therapeutics, Inc. (HALO) Given Average Rating of “Hold” by Analysts
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned a consensus rating of “Hold” from the ten analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.29.
Several research analysts recently issued reports on HALO shares. BidaskClub upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Barclays PLC reiterated an “overweight” rating and issued a $16.00 target price on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Friday, August 25th. ValuEngine raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Canaccord Genuity set a $16.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 26th.
COPYRIGHT VIOLATION WARNING: “Halozyme Therapeutics, Inc. (HALO) Given Average Rating of “Hold” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/halozyme-therapeutics-inc-halo-given-average-rating-of-hold-by-analysts.html.
A number of institutional investors have recently bought and sold shares of HALO. Wells Fargo & Company MN lifted its stake in Halozyme Therapeutics by 22.5% in the first quarter. Wells Fargo & Company MN now owns 303,626 shares of the biopharmaceutical company’s stock worth $3,935,000 after purchasing an additional 55,719 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Halozyme Therapeutics by 27.3% during the first quarter. Bank of New York Mellon Corp now owns 1,806,490 shares of the biopharmaceutical company’s stock valued at $23,412,000 after acquiring an additional 387,486 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of Halozyme Therapeutics during the first quarter valued at about $188,000. Sei Investments Co. raised its stake in shares of Halozyme Therapeutics by 0.8% during the first quarter. Sei Investments Co. now owns 309,725 shares of the biopharmaceutical company’s stock valued at $4,014,000 after acquiring an additional 2,605 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Halozyme Therapeutics by 37.2% during the first quarter. Parametric Portfolio Associates LLC now owns 52,784 shares of the biopharmaceutical company’s stock valued at $684,000 after acquiring an additional 14,308 shares during the last quarter. 85.08% of the stock is owned by institutional investors and hedge funds.
Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up 1.69% on Friday, hitting $16.25. The stock had a trading volume of 5,824,402 shares. The company’s market capitalization is $2.18 billion. Halozyme Therapeutics has a 1-year low of $8.18 and a 1-year high of $16.65. The firm has a 50-day moving average of $12.79 and a 200 day moving average of $13.23.
Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter last year, the firm posted ($0.21) earnings per share. The firm’s revenue was up 1.2% on a year-over-year basis. On average, equities analysts anticipate that Halozyme Therapeutics will post ($0.88) earnings per share for the current fiscal year.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.